Epstein-Barr virus latent membrane protein 1 peptide-HLA class I complex (EBV LMP1-HLA-I)

The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) peptide-HLA class I complex is a specific molecular target formed when processed fragments of the LMP1 viral oncogene are presented on the surface of infected cells by Human Leukocyte Antigen (HLA) molecules. LMP1 is a critical driver of EBV-associated malignancies, including nasopharyngeal carcinoma and various lymphomas, where it mimics CD40 signaling to promote cell survival and proliferation (Source: PubMed PMID: 30633415). Because LMP1 is an intracellular protein, it is not accessible to traditional antibody therapies; however, its degradation products (peptides) are displayed by HLA class I molecules, making the complex a viable target for T-cell receptor (TCR)-based therapies and TCR-like antibodies (Source: PubMed PMID: 28416511). Therapeutic strategies focusing on this complex aim to harness the immune system to selectively recognize and eliminate EBV-positive tumor cells while sparing healthy EBV-negative tissues. Clinical development in this area primarily involves TCR-engineered T cells (TCR-T) and bispecific molecules designed to bind specific peptide-HLA combinations, such as the LMP1-derived YLLEMLWRL peptide presented by HLA-A*02:01 (Source: PubMed PMID: 25609110). These approaches represent a precision medicine strategy for treating EBV-driven cancers that are often resistant to standard chemotherapy.

Other names

LMP1-MHC complexEBV LMP1 peptide-MHC class ILMP1-HLA-A*02:01 complexLMP1-derived peptide-HLA complexLMP1-HLA-A2

Recognition of the specific viral peptide-HLA complex by engineered T-cell receptors or TCR-like antibodies, leading to the directed cytotoxic destruction of EBV-infected or malignant cells.